Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as RET or NTRK fusions and pathogenic mutations of the BRAF and RAS genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient. Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver TERT, TP53, PIK3CA, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.

Dario de Biase, Andrea Repaci, Maria Concetta Nigro, Thais Maloberti, Francesca Carosi, Maria A. Pantaleo, et al. (2024). The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC). JOURNAL OF CLINICAL & TRANSLATIONAL ENDOCRINOLOGY, 1, 1-1 [10.1016/j.jcte.2024.100373].

The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)

Dario de Biase
;
Andrea Repaci;Maria Concetta Nigro;Thais Maloberti;Francesca Carosi;Maria A. Pantaleo;Giovanni Tallini;Margherita Nannini
2024

Abstract

Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as RET or NTRK fusions and pathogenic mutations of the BRAF and RAS genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient. Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver TERT, TP53, PIK3CA, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.
2024
Dario de Biase, Andrea Repaci, Maria Concetta Nigro, Thais Maloberti, Francesca Carosi, Maria A. Pantaleo, et al. (2024). The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC). JOURNAL OF CLINICAL & TRANSLATIONAL ENDOCRINOLOGY, 1, 1-1 [10.1016/j.jcte.2024.100373].
Dario de Biase; Andrea Repaci; Maria Concetta Nigro; Thais Maloberti; Francesca Carosi; Maria A. Pantaleo; Giovanni Tallini; Margherita Nannini...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/996505
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact